A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

Empagliflozin use in patients with type 2 diabetes (T2D) has not been shown to have a higher risk of urinary tract cancers ...

Rising demand for eco-friendly detergents and health supplements drives glucaric acid market growth amid increasing consumer wellness awareness globally.Austin, June 26, 2025 (GLOBE NEWSWIRE) -- The ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy ...

In the wake of Andrea's short tenure over the open Atlantic, tropical trouble can soon occur closer to home, with a risk of ...

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers at ...

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

Learn how insights and continuous therapy are transforming chronic lymphocytic leukemia care, empowering patients to live ...